Abstract:REINVENT4, a machine learning‐based de novo design tool, generates novel inhibitors‐modulators for targeting Heat Shock Protein 90 (HSP90), a protein essential in cancer association. The study has identified some benzimidazolone‐based inhibitors, which are rigorously analyzed for their drug‐likeness and binding affinity toward HSP90. This results in promising leads for further development as potential cancer therapies. The present study investigates the identification of novel heat shock protein‐90 (HSP90) inhibitors‐modulators employing de novo drug design methodologies. Precisely, a machine learning (ML) assisted de novo design tool, REINVENT4, was employed for generating novel molecules against a given set of known HSP90 inhibitors. Further, a series of cheminformatics analyses were undertaken to assess pharmacokinetic properties, evaluate binding affinity using docking, and predict absolute binding affinity using the KDeep tool to reduce the chemical space. Finally, three novel benzimidazole‐based drug‐like candidates viz. IM1, IM2, and IM3 were selected as potent inhibitors‐modulators for HSP90 protein. Docking‐based binding affinity of IM1, IM2, and IM3 was obtained as −11.30, −11.50, and −11.20 kcal/mol, respectively. Moreover, all identified protein‐ligand complex dynamic behavior has been extensively assessed through MD simulation for a 100 ns span, highlighting overall interaction stability and conformational rearrangements for protein bound with all selected compounds. The MM‐GBSA‐based binding free energy estimation for each complex demonstrated the superiority of identified compounds, as found to be −43.54, −38.34, and −25.50 kcal/mol for IM1, IM2, and IM3. Collectively, pharmacokinetics and drug‐like profile assessment of identified compounds, along with simulation trajectories, explained the potentiality of the compounds for modulating the activity of the HSP90.

Machine Learning Aided De Novo Design Identifies Novel Benzimidazolone Based Inhibitor‐Modulators for Heat Shock Protein 90 (HSP90)

Insight into the structural and dynamic properties of novel HSP90 inhibitors through DFT calculations and molecular dynamics simulations

In silico identification of small molecule modulators for disruption of Hsp90-Cdc37 protein-protein interaction interface for cancer therapeutic application

Dynamic Insights into Hsp90 Inhibitor Binding: Uncovering Intermediate States and Conformational Plasticity

Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Design, synthesis and biological studies of new isoxazole compounds as potent Hsp90 inhibitors

Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyri

Binding Mechanism of Inhibitors to Heat Shock Protein 90 Investigated by Multiple Independent Molecular Dynamics Simulations and Prediction of Binding Free Energy

Structural aspects of triazole derivatives as HSP90 inhibitors for the treatment of cancer: in silico studies

Discovery and development of heat shock protein 90 inhibitors.

Dynamics Revelation of Conformational Changes and Binding Modes of Heat Shock Protein 90 Induced by Inhibitor Associations

Design of A Flexible Cell-Based Assay for the Evaluation of Heat Shock Protein 70 Expression Modulators

Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Structure-based discovery of small molecule inhibitors of FKBP51-Hsp90 protein-protein interaction

Inhibition of the HSP90 homodimerization and HSP90-HIF1α interactions by employing small molecules at C-terminal ATP binding site of HSP90

Identification of new small molecules as dual FoxM1 and Hsp70 inhibitors using computational methods

Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation

Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors

Marine-Derived Compounds as Potential Inhibitors of Hsp90 for Anticancer and Antimicrobial Drug Development: A Comprehensive In Silico Study